Sun Pharma board okays buyback

Chennai | Updated on March 17, 2020 Published on March 17, 2020

Representative image   -  Bloomberg


The board of Sun Pharmaceutical Industries on Tuesday approved the buy-back of its equity shares from the open market at a maximum price of ₹425 a share for an aggregate maximum amount of up to ₹1,700 crore. The buyback size represents 9.83 per cent and 4.44 per cent of the total paid-up equity share capital and free reserves of the latest audited standalone financial statements and audited consolidated financial statements, respectively, for the financial year ended March 31, 2019. The company will buy back from the equity shareholders/beneficial owners of equity shares of the company, except promoters, members of promoter group and persons acting in concert. Our Bureau

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on March 17, 2020
This article is closed for comments.
Please Email the Editor